Founded with the mission to revolutionize heart failure treatment, Corinnova is pioneering healthcare solutions with a focus on congestive heart failure. The company's core product is a breakthrough minimally invasive, non-blood contacting cardiac assist device designed to treat acute heart failure. This innovative technology aims to address the needs of the short-term cardiac assist market, providing a critical solution for patients requiring up to seven days of support.
Corinnova has garnered significant attention and investment, notably from the Wellcome Trust, underscoring the potential impact of its technology. The company has achieved promising preclinical results, positioning itself as a leader in cardiac assist devices. By advancing this novel approach to heart failure treatment, Corinnova is poised to make a substantial impact on patient outcomes and the broader healthcare landscape.
